Semaglutide vs. Tirzepatide vs. Retatrutide: What the Trial Data Actually Shows

If you're trying to make sense of the GLP-1 landscape right now, you're not alone. There are three compounds that deserve serious attention, and the conversation around them has gotten noisy enough that it's worth laying out what the clinical trial data actually shows. Not the headlines. Not the social media takes. The primary endpoint data from the pivotal trials, the mechanisms that distinguish these drugs from each other, and the results that didn't go the way people expected.

We're going to walk through semaglutide, tirzepatide, and retatrutide. Each one works differently at the receptor level. Each one has a distinct evidence profile. And for folks who are trying to figure out which approach makes sense for them, the answer isn't "whichever one produces the most weight loss." It's whichever one best matches your metabolic picture, your clinical goals, and your risk profile. That's a physician decision, not a search engine decision.

How These Drugs Actually Work

All three of these compounds involve incretin signaling, but they do it in fundamentally different ways. The distinctions matter because they explain why the clinical outcomes are different.

Semaglutide is a GLP-1 receptor agonist. It activates one receptor. GLP-1 is a hormone your gut releases after you eat, and it does several things at once: it tells the pancreas to release insulin in a glucose-dependent way, it slows gastric emptying so food moves through your system more gradually, and it acts on appetite centers in the brain to reduce hunger. Semaglutide is a modified version of that natural hormone, engineered to last about a week in circulation rather than minutes. That's how a once-weekly injection works.

Tirzepatide is a dual agonist. It activates both the GLP-1 receptor and the GIP receptor. GIP, glucose-dependent insulinotropic polypeptide, is the other major incretin hormone. It enhances insulin secretion through a separate pathway and appears to have additive effects on appetite, body composition, and fat metabolism when combined with GLP-1 signaling. Think of it as two signals working through two distinct channels rather than one signal working harder through a single channel.

Retatrutide takes it further. It's a triple agonist, hitting GLP-1, GIP, and the glucagon receptor. Glucagon is the hormone that opposes insulin. It raises blood glucose, but it also increases energy expenditure and promotes fat oxidation in the liver. In a weight loss context, that third receptor adds a thermogenic component. Your body is not just eating less and absorbing more slowly, it's also burning more energy. The Phase 2 data reflects this, and we'll get to that.

Semaglutide: The Most Studied

Semaglutide has the deepest evidence base of the three. The STEP trial program studied it for weight management across five major trials, and the results were consistent. In STEP 1, the landmark trial, 1,961 adults with obesity but without diabetes lost an average of 14.9% of their body weight over 68 weeks on semaglutide 2.4 mg, compared to 2.4% with placebo. STEP 5 extended that to 104 weeks and found the weight loss held at about 15.2%. That's not a flash-in-the-pan result. It's durable over two years with continued treatment.

But here's where semaglutide separates itself from the other two, at least for now. It's the only one with a completed cardiovascular outcomes trial. The SELECT trial enrolled 17,604 adults with overweight or obesity who had established cardiovascular disease but did not have diabetes. Mean follow-up was about 40 months. The primary endpoint was major adverse cardiovascular events, what we call MACE: cardiovascular death, nonfatal heart attack, or nonfatal stroke. Semaglutide reduced MACE by 20%, with a hazard ratio of 0.80. That's a meaningful reduction. It also reduced all-cause mortality by 19% and heart failure hospitalization by 18%.

That SELECT data changed the clinical conversation. It established that semaglutide isn't just a weight loss drug. It has cardiovascular protective effects that appear to go beyond what weight loss alone would explain. Whether that's from direct vascular effects, anti-inflammatory mechanisms, or both is still being worked out. But the outcome data is there, published in the New England Journal of Medicine, and it's robust.

Tirzepatide: The Strongest Weight Loss Data

If we're talking raw weight loss numbers, tirzepatide produces the largest reductions of any approved medication. The SURMOUNT-1 trial enrolled about 2,539 adults with obesity and found dose-dependent weight loss of 16.0%, 21.4%, and 22.5% at the 5 mg, 10 mg, and 15 mg doses respectively, over 68 weeks. Placebo was 2.4%. At the highest dose, roughly one in three participants lost more than 25% of their body weight.

Those are striking numbers. To put it in context, the average participant lost about 52 pounds at the top dose. That's surgical territory without surgery.

In type 2 diabetes, the SURPASS trials showed tirzepatide was not only effective at lowering blood sugar but was directly compared against semaglutide in SURPASS-2 and came out ahead on both HbA1c reduction and weight loss. It's a meaningful head-to-head result.

The cardiovascular outcomes story is more nuanced. The SURPASS-CVOT trial, published in 2025, compared tirzepatide against dulaglutide (another GLP-1 agonist, not placebo) in about 8,200 adults with type 2 diabetes and established atherosclerotic cardiovascular disease over a median of four years. Tirzepatide was noninferior to dulaglutide on MACE, but did not achieve statistical superiority. On an expanded MACE endpoint that included coronary revascularization, tirzepatide did show a statistically significant reduction. All-cause mortality was also lower.

The important nuance here: SURPASS-CVOT was not placebo-controlled. It was tested against an active comparator that itself has cardiovascular benefit. So the trial doesn't tell us "is tirzepatide better than nothing for your heart?" It tells us "is tirzepatide better than another GLP-1 agonist for your heart?" And the answer appears to be comparable, possibly modestly better on some endpoints.

Retatrutide: The Newest, the Strongest Signal

Retatrutide is not yet approved. It's in Phase 3 trials. But the Phase 2 data, published in the New England Journal of Medicine in 2023, produced weight loss numbers that exceeded anything we'd seen before.

In a 48-week dose-ranging study of adults with obesity, the highest dose (12 mg) produced an average body weight reduction of 24.2%. For context, that's nearly 10 percentage points beyond what semaglutide achieved at its best in the STEP program, and it's approaching the 25-30% range that was previously only achievable with bariatric surgery.

The first Phase 3 result, TRIUMPH-4, was published in late 2025. It studied retatrutide in 411 adults with obesity and knee osteoarthritis. Weight loss reached 26.4% at the 9 mg dose and 28.7% at 12 mg over 68 weeks. About one in seven participants became completely pain-free in their knee. Those are serious numbers.

That said, there's an important safety signal that emerged in Phase 3 that wasn't apparent in Phase 2. Dysesthesia, a numbness or tingling sensation, occurred in about 21% of participants at the 12 mg dose compared to less than 1% on placebo. The clinical significance of this isn't fully characterized yet. It may be reversible. It may be dose-related. But it's a new finding that didn't show up in the smaller earlier trial, and it needs to be tracked carefully as more Phase 3 data comes in.

Retatrutide has seven additional Phase 3 trials reading out in 2026, covering obesity alone, type 2 diabetes, sleep apnea, chronic low back pain, cardiovascular and kidney outcomes, and metabolic liver disease. We'll know a lot more by the end of this year.

Where the Data Came Up Short

This is the section that most articles skip, and it's arguably the most important one.

The EVOKE trial was a Phase 3 study of semaglutide in 3,808 adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. The rationale was reasonable: GLP-1 receptors are present in the brain, there was preclinical evidence of neuroprotective effects, and insulin resistance is implicated in Alzheimer's pathophysiology. There was genuine scientific basis for testing this.

The trial ran for three years. The primary endpoint was change in the Clinical Dementia Rating sum of boxes, which is a validated measure of cognitive and functional decline. The result was negative. Semaglutide showed no significant difference from placebo on cognitive decline. The curves were essentially identical over three years. Interestingly, semaglutide did show some improvement in Alzheimer's fluid biomarkers in cerebrospinal fluid, but that biological signal did not translate into any detectable clinical benefit. Novo Nordisk discontinued the planned one-year extension.

Why does this matter? Because it establishes a boundary. GLP-1 agonists do a lot of things well, cardiovascular protection, weight management, joint health, liver disease, kidney protection. But they don't appear to slow or prevent Alzheimer's disease. The EVOKE result is a good reminder that mechanism-based hypotheses need to be tested, and sometimes the data says no. That's how medicine works. You don't get to keep the hypothesis when the trial disagrees.

Non-Weight-Loss Effects Worth Knowing About

The story around these drugs has expanded considerably beyond body weight. Here's what the evidence supports, where it's preliminary, and where the gaps remain.

Cardiovascular protection is the most established non-weight effect. Semaglutide's SELECT trial is the clearest dataset: 20% MACE reduction, 19% all-cause mortality reduction, 18% reduction in heart failure hospitalization. That's in overweight and obese adults with prior cardiovascular disease but without diabetes. Tirzepatide's SURPASS-CVOT showed noninferiority to an active GLP-1 comparator. Retatrutide's cardiovascular outcomes data is still pending.

Osteoarthritis and joint health data is encouraging. Semaglutide's STEP 9 trial showed meaningful pain improvement, and the cartilage thickness data on MRI suggests a direct tissue-protective effect beyond mechanical unloading. Retatrutide's TRIUMPH-4 showed similar pain benefit alongside its greater weight loss. For folks with obesity and joint disease, this is an area where the risk-benefit calculation is becoming increasingly clear.

Liver disease (MASLD/NASH) is a rapidly evolving story. Semaglutide is FDA-approved for metabolic-associated liver disease with fibrosis as of 2025. About 63% of treated participants achieved resolution of liver inflammation without fibrosis worsening. Tirzepatide showed comparable results in its Phase 2 SYNERGY-NASH trial. For individuals with concurrent obesity and liver disease, these are among the strongest non-weight-loss indications.

Kidney disease. The FLOW trial showed semaglutide reduced kidney disease progression by 21% in folks with type 2 diabetes and chronic kidney disease. That's a meaningful benefit, particularly when combined with SGLT2 inhibitors, which appear to protect through a different mechanism. The two drug classes look additive.

Sleep apnea data is promising but still early. There's epidemiological evidence that GLP-1 agonist use is associated with about 40% lower rates of obstructive sleep apnea compared to untreated populations. But the study quality is limited. Short follow-up, inconsistent measurement methods, and confounding from weight loss itself make it difficult to separate direct drug effects from indirect weight-mediated effects. Retatrutide has a dedicated Phase 3 sleep apnea trial underway, which should provide cleaner data.

How to Think About Choosing

This isn't a ranking exercise. It's a clinical decision that depends on what you're trying to accomplish and what your metabolic starting point looks like.

If cardiovascular risk reduction is a primary goal, semaglutide currently has the strongest evidence, with a placebo-controlled outcomes trial showing clear mortality and MACE benefit. If the primary goal is maximum weight reduction and you're otherwise healthy, tirzepatide at appropriate doses produces the most weight loss of any approved medication. If retatrutide reaches the market, its efficacy profile may exceed both, but it's not yet available and its safety profile is still being characterized.

What matters more than which drug has the biggest number is whether the drug is being used within a proper clinical framework. These are prescription medications. They interact with insulin sensitivity, glucose metabolism, gastric motility, and multiple organ systems. They require baseline labs, metabolic assessment, appropriate dosing, titration schedules, and ongoing physician oversight. That's not a disclaimer. That's the bare minimum for using them safely and effectively.